Note 2 - Summary Of Significant Accounting Policies (Detail) (USD $)	3 Months Ended
Sep. 30, 2012	Sep. 30, 2011	Jun. 30, 2012
Cash, Uninsured Amount	$ 1,443,000		$ 863,000
Depreciation	1,161,000	1,319,000
Research and Development Expense	$ 1,652,000	$ 1,164,000
Incremental Common Shares Attributable to Contingently Issuable Shares (in Shares)	345,000	319,000

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References+ Details

Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.

+ References+ Details

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References+ Details